Pay in 4 interest-free payments of $5.82 Learn more
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6
To see how this framework supports sustainable wellness, Read the Expert Breakdown of Sprout Health Weight Loss
Add-on to 1-3 oral anti-hyperglycemic agents (metformin, sulfonylurea, or SGLT-2 inhibitor) SURPASS-4 (NCT03730662) was a 104-week open-label trial (52-week primary endpoint) that randomized 2002 adult patients with type 2 diabetes mellitus with increased cardiovascular risk to subcutaneous MOUNJARO 5 mg, MOUNJARO 10 mg, MOUNJARO 15 mg once weekly, or insulin glargine 100 units/mL once daily (1:1:1:3 ratio) on a background of metformin (95%) and/or sulfonylureas (54%) and/or SGLT2 inhibitors (25%)
For researchers who are considering switching between the two , the conversion chart provides detailed guidance on transitioning safely
If youre unsure about what to do or have missed multiple doses, our team is here to help
A Different Way To Manage The Routine Without Burning Out Most people manage tracking with ad hoc notes, photos, or memory because its familiar and seems low-friction
